Welcome to our dedicated page for Bemis news (Ticker: BMS), a resource for investors and traders seeking the latest updates and insights on Bemis stock.
The symbol BMS is associated in the supplied news items with Bristol Myers Squibb, referenced as "BMS" and trading on the New York Stock Exchange under the symbol BMY. The news articles provided focus on Bristol Myers Squibb as a global biopharmaceutical company whose stated mission is to discover, develop and deliver medicines that help patients prevail over serious diseases.
On this news-focused page, readers can review coverage drawn from those releases, which describe topics such as an agreement with the U.S. government regarding Eliquis, an oral anticoagulant, including plans to make Eliquis available to the Medicaid program for free and to donate active pharmaceutical ingredient to support supply resilience. Other news items detail clinical research developments, including the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease, where Bristol Myers Squibb is evaluating Cobenfy, a treatment approved for schizophrenia in adults and being studied for additional indications.
Additional articles in the provided input describe Bristol Myers Squibb’s activities in cell therapy and immunology. One release outlines a definitive agreement to acquire Orbital Therapeutics, a biotechnology company working on RNA medicines designed to reprogram the immune system in vivo, including the preclinical candidate OTX-201. Another release discusses the creation of a new independent biopharmaceutical company with Bain Capital, focused on developing therapies for autoimmune diseases using assets in-licensed from Bristol Myers Squibb.
Investors and observers using a BMS news page based on this feed can read about these kinds of developments, including agreements with government entities, progress in clinical trials, acquisitions that expand research platforms, and collaborations to advance immunology assets. The articles originate from sources such as Business Wire and PR Newswire and present Bristol Myers Squibb’s own descriptions of its programs and transactions.
Bristol Myers Squibb (NYSE: BMS) announced a collaboration with Microsoft on January 20, 2026 to deploy U.S. FDA-cleared radiology AI algorithms for lung cancer detection via Microsoft’s Precision Imaging Network. The initiative aims to automatically analyze X-ray and CT images to surface hard-to-detect lung nodules, accelerate identification of potential Non‑Small Cell Lung Cancer (NSCLC) cases, and route patients into care pathways.
The program emphasizes expanding early detection and follow-up in medically underserved communities, leveraging workflow tools to address that >50% of patients with incidental findings are lost to follow-up and noting Microsoft’s network reaches more than 80% of U.S. hospitals.
Bristol Myers Squibb (NYSE: BMS) announced an agreement with the U.S. government to improve affordability and supply resilience for Eliquis (apixaban).
Key items: Eliquis will be provided free to the Medicaid program starting January 1, 2026; the company will donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to the U.S. Strategic Active Ingredient Reserve at no cost; BMS will receive three years of tariff relief; and BMS will enable direct-to-patient discounted access (about 80% off list price) for several branded medicines. The agreement’s specific commercial terms remain confidential. BMS reaffirmed a prior commitment to invest $40 billion in the United States over five years and said it will expand domestic production to support onshoring.
Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.
The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.
Bristol Myers Squibb (NYSE: BMY) will acquire Orbital Therapeutics for $1.5 billion cash at closing, adding Orbital’s lead preclinical program OTX-201 and a proprietary RNA platform that combines circular and linear RNA, targeted LNP delivery, and AI-driven design.
The deal aims to expand BMS’s cell therapy portfolio by enabling in vivo CAR T approaches intended to reduce treatment burden and broaden patient access for autoimmune diseases. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period, and accounting treatment will be determined at close.
Bristol Myers Squibb (NYSE: BMY) and Bain Capital have announced the formation of a new independent biopharmaceutical company focused on developing immunology therapies for autoimmune diseases. The new company launches with $300 million in financing led by Bain Capital and five immunology assets in-licensed from BMS.
The portfolio includes three clinical-stage and two Phase 1-ready investigational medicines, with the most advanced being afimetoran, a TLR7/8 inhibitor in Phase 2 trials for lupus, and BMS-986322, a TYK2 inhibitor that showed positive Phase 2 results in plaque psoriasis. BMS will maintain a 20% equity stake in the new company and receive royalties and milestones tied to asset success.
Daniel S. Lynch will serve as Executive Chairman and interim CEO, with representatives from both BMS and Bain Capital joining the board of directors.
K36 Therapeutics announced multiple poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting the first clinical data for their MMSET/NSD2 inhibitors, KTX-1001 and KTX-1029. The presentations will cover the dose escalation part of KTX-1001's Phase 1 study, showing increased exposure and decreased H3K36me2 biomarker, indicating clear target engagement. KTX-1029, a potent and selective MMSET inhibitor, demonstrated efficacy in preclinical models. Together, these data support the rationale for targeting MMSET in multiple myeloma. The favorable tolerability profile of KTX-1001 and promising clinical activity suggest its potential as a first-in-class therapy for t(4;14) multiple myeloma patients.
Summary not available.
AVEO Oncology reported Q3 2021 revenue of $15.2 million, significantly up from $3.6 million in Q3 2020, driven largely by FOTIVDA® sales of $14.3 million. The company saw a 113% increase in quarterly revenue from the previous quarter, bolstered by the growing demand for FOTIVDA in treating relapsed/refractory renal cell carcinoma. Enrollment for the Phase 3 TiNivo-2 trial of tivozanib in combination with OPDIVO® has begun. Additionally, ficlatuzumab received Fast Track Designation from the FDA. AVEO ended the quarter with $94 million in cash and anticipates maintaining operations for at least 12 months.
